General Info

Sangamo BioSciences, founded in 1995 and located in Richmond, Calif., is focused on the research and development of novel transcription factors for the regulation of gene expression. The company s most advanced therapeutic development program involves the use of transcription factors for the treatment of cardiovascular disease. Its other therapeutics development programs are focused on cancer, neuropathic pain, ophthalmic and infectious diseases. Sangamo s proprietary technology enables the engineering of transcription factors known as zinc finger DNA binding proteins. By engineering ZFPs so that they can recognize a specific gene, Sangamo has created ZFP transcription factors that can control gene expression and cell function. The company is developing ZFP TFs as a fundamentally enabling technology for commercial applications in human therapeutics, pharmaceutical discovery, agriculture and industrial biotechnology. More than 20 leading pharmaceutical and biotechnology companies have utilized Sangamo s research. The company trades on NASDAQ under the symbol SGMO.